Press coverage about NeuroMetrix (NASDAQ:NURO) has been trending negative recently, Alpha One Sentiment Analysis reports. Alpha One, a subsidiary of Accern, ranks the sentiment of news coverage by monitoring more than twenty million blog and news sources in real-time. Alpha One ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. NeuroMetrix earned a coverage optimism score of -0.27 on Alpha One’s scale. Alpha One also assigned news stories about the medical device company an impact score of 100 out of 100, indicating that recent news coverage is extremely likely to have an impact on the stock’s share price in the near term.

Here are some of the news stories that may have effected AlphaOne Sentiment’s analysis:

Insider Buying and Selling by Quarter for NeuroMetrix (NASDAQ:NURO)

NURO has been the subject of a number of research analyst reports. Zacks Investment Research lowered shares of NeuroMetrix from a “hold” rating to a “sell” rating in a research report on Wednesday, April 26th. ValuEngine lowered shares of NeuroMetrix from a “sell” rating to a “strong sell” rating in a research report on Friday, June 2nd. Finally, HC Wainwright set a $16.00 price objective on shares of NeuroMetrix and gave the company a “buy” rating in a research report on Thursday.

Shares of NeuroMetrix (NASDAQ NURO) traded down 4.33% on Friday, hitting $2.87. 77,713 shares of the stock were exchanged. The firm’s market capitalization is $3.64 million. NeuroMetrix has a one year low of $2.76 and a one year high of $16.00. The company has a 50-day moving average price of $2.69 and a 200-day moving average price of $1.21.

NeuroMetrix (NASDAQ:NURO) last announced its earnings results on Thursday, April 20th. The medical device company reported ($7.28) EPS for the quarter, missing the consensus estimate of ($3.92) by $3.36. The company had revenue of $4.31 million for the quarter, compared to the consensus estimate of $4.17 million. NeuroMetrix had a negative return on equity of 175.24% and a negative net margin of 99.95%. Equities research analysts expect that NeuroMetrix will post ($10.50) earnings per share for the current year.

TRADEMARK VIOLATION WARNING: “NeuroMetrix (NURO) Receives Daily News Impact Rating of -0.27” was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this report on another website, it was copied illegally and republished in violation of international trademark and copyright legislation. The legal version of this report can be read at https://www.thecerbatgem.com/2017/06/16/neurometrix-nuro-getting-critical-media-coverage-study-finds-updated-updated-updated.html.

About NeuroMetrix

NeuroMetrix, Inc is a healthcare company combining bioelectrical and digital medicine to address chronic health conditions, including chronic pain, sleep disorders and diabetes. The Company is engaged in the sale of medical equipment, and consumables and accessories. It has two principal product lines: Wearable neuro-stimulation therapeutic devices and Point-of-care neuropathy diagnostic tests.

Receive News & Stock Ratings for NeuroMetrix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroMetrix Inc. and related stocks with our FREE daily email newsletter.